Relationship between HBV genotypes/sub -genotypes of hepatitis B virus and antiviral therapy
	    		
		   		
		   			 
		   		
	    	
    	 
    	10.3760/cma.j.issn.1008-6706.2015.13.008
   		
        
        	
        		- VernacularTitle:乙型肝炎病毒基因型亚型与抗病毒疗效关系的研究
- Author:
	        		
		        		
		        		
			        		Yanfang HU
			        		
			        		;
		        		
		        		
		        		
			        		Miao WANG
			        		
			        		;
		        		
		        		
		        		
			        		Qinying WANG
			        		
			        		
		        		
		        		
		        		
 
			        		
			        		
		        		 
- Publication Type:Journal Article
- Keywords:
        			
	        			
	        				
	        				
			        		
				        		Chronic Hepatitis B;
			        		
			        		
			        		
				        		Genotype;
			        		
			        		
			        		
				        		Adefovir Dipivoxil;
			        		
			        		
			        		
				        		Entecavir
			        		
			        		
	        			
        			
        		
- From:
	            		
	            			Chinese Journal of Primary Medicine and Pharmacy
	            		
	            		 2015;(13):1941-1943
	            	
            	
- CountryChina
- Language:Chinese
- 
		        	Abstract:
			       	
			       		
				        
				        	Objective To investigate the relationship between the genotype /sub -genotype and antiviral treatment.Methods The clinical data of 159 patients with chronic HBV infections were collected,who were treated by adefovir dipivoxil (10mg/d)or entecavir(0.5mg/d)according to the disease′s conditions.The genotypes and subtypes of hepatitis B virus were determined by Nested polymerase chain reaction(nt PCR).The levels of serum HBVDNA replication,ALT levels and HBV serologic markers were detected pre or post -treatment 24 weeks, 48 weeks.Observed the relationship between the HBV genotypes/sub -genotypes and the antiviral efficacy of adefovir dipivoxil or entecavir treatment.Results After 24 weeks of adefovir dipivoxil therapy,ALT normalization rate of subgenotype Ba and subgenotype C2 was 66.7% vs 66.2%(χ2 =0.74,P >0.05),HBeAg negative conversion rate of two subgenotypes was 27.3% vs 23.1%(χ2 =0.10,P >0.05),HBVDNA negative conversion rate of two sub genotype Ba and subgenotype C2 was 33.3% vs 30.9%(χ2 =0.03,P >0.05),respectively.After treatment for 48 weeks,ALT normalization rates of subgenotype Ba and subgenotype C2 were 83.3% vs 82.4%(χ2 =0.01,P >0.05),HBeAg negative conversion rates of two subgenotypes were 45.5% vs 34.4%(χ2 =0.49,P >0.05 ),HBVDNA negative conversion rates of two subgenotypes were 58.3% vs 48.5%(χ2 =0.39,P >0.05).After 24 weeks of entecavir therapy, ALT normalization rates of subgenotype Ba and subgenotype C2 were 71.4% vs 69.6%(χ2 =0.02,P >0.05 ), HBeAg negative conversion rates of two subgenotypes were 33.3% vs 30.8%(χ2 =0.03,P >0.05 ),HBVDNA negative conversion rates of two subgenotypes were 42.9% vs 39.3%(χ2 =0.06,P >0.05 ),respectively.After treatment for 48 weeks,ALT normali zation rates of subgenotype Ba and subgenotype C2 were 85.7% vs 83.9%(χ2 =0.03,P >0.05),HBeAg negative conversion rates of two subgenotypes were 50.0% vs 44.9%(χ2 =0.10, P >0.05),HBVDNA negative conversion rates of two subgenotypes were 71.4%vs 67.8%(χ2 =0.07,P >0.05). Conclusion The study showed that genotype C(C2)is a predominant HBV genotype among people with chronic HBV infections in Shanxi province.HBV subgenotypes Ba and C2 have no significant difference in virologic,biochemi-cal,and immunologic response to ADV or ETV.